[HTML][HTML] Comorbidities, multimorbidity and COVID-19
The influence of comorbidities on COVID-19 outcomes has been recognized since the
earliest days of the pandemic. But establishing causality and determining underlying …
earliest days of the pandemic. But establishing causality and determining underlying …
[HTML][HTML] COVID-19-associated fungal infections
Abstract Coronavirus disease 2019 (COVID-19)-associated invasive fungal infections are an
important complication in a substantial number of critically ill, hospitalized patients with …
important complication in a substantial number of critically ill, hospitalized patients with …
[HTML][HTML] SARS-CoV-2 infection and persistence in the human body and brain at autopsy
Abstract Coronavirus disease 2019 (COVID-19) is known to cause multi-organ dysfunction,–
during acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
during acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[HTML][HTML] Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection
M Patone, XW Mei, L Handunnetthi, S Dixon… - Nature medicine, 2022 - nature.com
Although myocarditis and pericarditis were not observed as adverse events in coronavirus
disease 2019 (COVID-19) vaccine trials, there have been numerous reports of suspected …
disease 2019 (COVID-19) vaccine trials, there have been numerous reports of suspected …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2021 - thelancet.com
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
COVID-19 and cardiovascular disease: from bench to bedside
A pandemic of historic impact, coronavirus disease 2019 (COVID-19) has potential
consequences on the cardiovascular health of millions of people who survive infection …
consequences on the cardiovascular health of millions of people who survive infection …
[HTML][HTML] Genetic mechanisms of critical illness in COVID-19
Host-mediated lung inflammation is present, and drives mortality, in the critical illness
caused by coronavirus disease 2019 (COVID-19). Host genetic variants associated with …
caused by coronavirus disease 2019 (COVID-19). Host genetic variants associated with …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …